-
Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval
•
Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that uses electric fields to target and eliminate cancer cells, is undergoing a strategic restructuring and portfolio prioritization. The company plans to release 200 staff members, representing approximately a 13% reduction in its workforce, with the…
-
AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial
•
AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class antibody-drug conjugate (ADC) telisotuzumab-vedotin, which targets c-Met protein-overexpressing, EGFR-wild-type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial results showed an overall response rate (ORR) of 35% in patients with high c-Met levels and 23%…
-
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development…
-
Jiangsu Hengrui Receives NMPA Approval for Esophageal Cancer and Breast Cancer Clinical Trials
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II study for adebrelimab (SHR-1316) in combination with neoadjuvant chemotherapy for locally advanced surgically resectable esophageal squamous cell carcinoma (ESCC) in the perioperative setting. Additionally, the Chinese pharmaceutical company…
-
Asieris Pharmaceuticals’ Hexvix for Bladder Cancer Accepted for Review by China’s NMPA
•
Asieris Pharmaceuticals (SHA: 688176), a specialist in urogenital cancer based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for its Hexvix (APL-1706) for the diagnosis and management of bladder cancer. Hexvix stands as the only globally approved agent…
-
Jiangxi Jemincare’s KRAS Inhibitor Earns Breakthrough Designation from China’s CDE for NSCLC
•
The China Center for Drug Evaluation (CDE) website has indicated that Jiangxi Jemincare Group’s proprietary small-molecule KRAS inhibitor, JMKX001899, has been granted breakthrough therapy designation (BTD) status for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation in patients who have previously received…
-
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
•
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm Prism BioLab to discover peptide-mimicking small molecule inhibitors (SMIs) for up to three protein-protein interaction (PPI) targets. Under the agreement, Lilly will be responsible for the clinical development and commercialization of any successful candidates, while…
-
Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China
•
The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio (mosunetuzumab) and AnHeart Therapeutics’ taletrectinib are on track to receive priority review status. Mosunetuzumab, a bispecific antibody targeting CD20 and CD3, has already been approved for the treatment of adult recurrent refractory follicular lymphoma (FL)…
